Reducedhumoral response against variants of concern in childhood solid cancer patients compared to adult patients and healthy children after SARS-CoV-2 vaccination

Introduction Although there is extended research on the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in adult cancer patients (ACP), the immunogenicity to the variants of concern (VOCs) in childhood cancer patients (CCP) and safety profiles are now little known. Methods A prospective, multi-center cohort study was performed by recruiting children with a solid cancer diagnosis and childhood healthy control (CHC) to receive standard two-dose SARS-CoV-2 vaccines. An independent ACP group was included to match CCP in treatment history. Humoral response to six variants was performed and adverse events were followed up 3 months after vaccination. Responses to variants were compared with ACP and CHC by means of propensity score-matched (PSM) analysis. Results The analysis included 111 CCP (27.2%, median age of 8, quartile 5.5–15 years), 134 CHC (32.8%), and 163 ACP (40.0%), for a total 408 patients. Pathology included carcinoma, neural tumors, sarcoma, and germ cell tumors. Median chemotherapy time was 7 (quartile, 5–11) months. In PSM sample pairs, the humoral response of CCP against variants was significantly decreased, and serology titers (281.8 ± 315.5 U/ml) were reduced, as compared to ACP (p< 0.01 for the rate of neutralization rate against each variant) and CHC (p< 0.01 for the rate of neutralization against each variant) groups. Chemotherapy time and age (Pearson r ≥ 0.8 for all variants) were associated with the humoral response against VOCs of the CHC group. In the CCP group, less than grade II adverse events were observed, including 32 patients with local reactions, and 29 patients had systemic adverse events, including fever (n = 9), rash (n = 20), headache (n = 3), fatigue (n = 11), and myalgia (n = 15). All reactions were well-managed medically. Conclusions The humoral response against VOCs after the CoronaVac vaccination in CCP was moderately impaired although the vaccine was safe. Age and chemotherapy time seem to be the primary reason for poor response and low serology levels.

[1]  W. Jantarabenjakul,et al.  Immune Response after 2 Doses of BNT162b2 mRNA COVID-19 Vaccinations in Children and Adolescents with Cancer and Hematologic Diseases , 2022, Asian Pacific journal of cancer prevention : APJCP.

[2]  D. Micic,et al.  Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis , 2022, Journal of Hematology & Oncology.

[3]  L. Pickering,et al.  Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer , 2022, The Lancet.

[4]  Emily E. Johnston,et al.  SARS‐CoV‐2 vaccine acceptability among caregivers of childhood cancer survivors , 2021, Pediatric blood & cancer.

[5]  Lei Zhao,et al.  Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China , 2021, Frontiers in Medicine.

[6]  Nianqi Liu,et al.  Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis , 2021, Journal for ImmunoTherapy of Cancer.

[7]  P. Nathan,et al.  Subsequent malignant neoplasms in the Childhood Cancer Survivor Study: Occurrence of cancer types in which human papillomavirus is an established etiologic risk factor , 2021, Cancer.

[8]  R. Kotecha COVID‐19 vaccination for children with cancer , 2021, Pediatric blood & cancer.

[9]  N. André,et al.  Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study , 2021, The Lancet Oncology.

[10]  Changgui Li,et al.  Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial , 2021, The Lancet Infectious Diseases.

[11]  P. Dormitzer,et al.  Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents , 2021, The New England journal of medicine.

[12]  M. Malim,et al.  Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study , 2021, The Lancet Oncology.

[13]  G. Pravettoni,et al.  Current Perspectives: SARS-CoV-2 vaccines for cancer patients: a call to action , 2021, European Journal of Cancer.

[14]  Arthur S Slutsky,et al.  Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.

[15]  Daniel K Choi,et al.  Vaccination in pediatric cancer survivors: Vaccination rates, immune status, and knowledge regarding compliance , 2020, Pediatric blood & cancer.

[16]  R. Kotecha Challenges posed by COVID-19 to children with cancer , 2020, The Lancet Oncology.

[17]  Elizabeth M. Wells,et al.  Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort. , 2018, The Lancet. Oncology.

[18]  Gang Liu,et al.  A cohort study , 2018 .

[19]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[20]  C. Blyth,et al.  Immunogenicity and safety of single‐dose, 13‐valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients , 2017, Cancer.

[21]  I. Barr,et al.  Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer , 2015, Cancer medicine.

[22]  D. Bates,et al.  Linear Mixed-Effects Models using 'Eigen' and S4 , 2015 .

[23]  P. Nathan,et al.  Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. , 2014, The Lancet. Oncology.

[24]  L. Kremer,et al.  Influenza vaccination in children being treated with chemotherapy for cancer. , 2013, The Cochrane database of systematic reviews.

[25]  J. McCullers,et al.  Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. , 2011, The Journal of infectious diseases.

[26]  P. Austin Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[27]  Stefano M. Iacus,et al.  cem: Software for Coarsened Exact Matching , 2009, Journal of Statistical Software.

[28]  F. Schmidt Meta-Analysis , 2008 .

[29]  Gary King,et al.  Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference , 2007, Political Analysis.

[30]  Paul Tseng,et al.  Relaxation Methods for Minimum Cost Ordinary and Generalized Network Flow Problems , 1988, Oper. Res..

[31]  W. Conover Statistical Methods for Rates and Proportions , 1974 .

[32]  Hay Dn,et al.  Call for action. , 1971, Nursing mirror and midwives journal.

[33]  Tingting Li,et al.  The long-term impact of tumor burden in pT3N0M0 esophageal squamous cell carcinoma , 2019, Medicine.